What new antibiotics is Wockhardt developing?

Wockhardt is developing ZAYNICH, FOVISCU, MIQNAF, and ODRATE, targeting various resistant bacterial infections.

How is Wockhardt addressing sepsis and pneumonia?

The company's flagship antibiotic, ZAYNICH, uses a novel beta-lactam enhancer for treating sepsis and hospital-associated pneumonia.

What other products does Wockhardt offer?

Wockhardt also provides insulin analogs, glucagon-like peptide-1 agonists, recombinant vaccines, and insulin delivery devices.

Home / Business and Economy / Wockhardt's New Antibiotics Fight Superbugs

Wockhardt's New Antibiotics Fight Superbugs

1 Dec, 2025

•

Summary

Wockhardt is developing novel antibiotics for resistant infections.
New treatments target sepsis and pneumonia with unique mechanisms.
The company also offers insulin analogs and recombinant vaccines.

Wockhardt's New Antibiotics Fight Superbugs

Wockhardt Limited, a global pharmaceutical and biotech firm, is at the forefront of developing novel antibiotics to combat the escalating threat of drug-resistant bacteria. The company's pipeline includes ZAYNICH, a dual-action antibiotic targeting sepsis and pneumonia, and FOVISCU for resistant gram-negative infections.

Further innovation includes MIQNAF for azithromycin-resistant pathogens and ODRATE, a daily combination therapy for outpatient parenteral antimicrobial therapy. These advancements aim to provide critical solutions for challenging infections and address the growing global health crisis.